» Articles » PMID: 20605601

Overexpression of ATA1/SLC38A1 Predicts Future Recurrence and Death in Chinese Patients with Hilar Cholangiocarcinoma

Overview
Journal J Surg Res
Specialty General Surgery
Date 2010 Jul 8
PMID 20605601
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

System A amino acid transporter is a Na+-dependent active transport system, mediating the uptake of amino acids, dysregulation of which has been found to be associated with malignant transformation in mammalian cells. However, the role of ATA1 in hilar cholangiocarcinoma is unclear. Here, we investigated ATA1 expression and determined its clinical significance in hilar cholangiocarcinoma. Tissue microarray blocks containing tumor specimens obtained from 48 patients were constructed. Expression of ATA1 in these specimens was analyzed using immunohistochemical studies. ATA1 overexpression was observed in 22 cases (44.9%). Overexpression of ATA1 was significantly associated with lymph node metastases. ATA1 expression has a significant correlation with recurrence and poor survival in univariate analyses. Multivariate analyses revealed that ATA1 was an independent predictor for future recurrence in patients with cholangiocarcinoma. Increased expression of ATA1 is frequent in human hilar cholangiocarcinoma and significantly correlated with the progression of cholangiocarcinoma, suggesting the importance of ATA1 in cancer development and progression. ATA1 expression may be used to predict recurrence and death and can serve as a promising target for therapy of this malignancy.

Citing Articles

Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases.

Ma Q, Hui Y, Huang B, Yang B, Li J, Fan T Transl Cancer Res. 2023; 12(1):46-64.

PMID: 36760376 PMC: 9906058. DOI: 10.21037/tcr-22-2203.


High Expression Levels of SLC38A1 Are Correlated with Poor Prognosis and Defective Immune Infiltration in Hepatocellular Carcinoma.

Liu Y, Yang Y, Jiang L, Xu H, Wei J J Oncol. 2021; 2021:5680968.

PMID: 34697542 PMC: 8541878. DOI: 10.1155/2021/5680968.


Gilteritinib Inhibits Glutamine Uptake and Utilization in -ITD-Positive AML.

Zavorka Thomas M, Lu X, Talebi Z, Jeon J, Buelow D, Gibson A Mol Cancer Ther. 2021; 20(11):2207-2217.

PMID: 34518298 PMC: 8687141. DOI: 10.1158/1535-7163.MCT-21-0071.


FOXK1 plays an oncogenic role in the progression of hilar cholangiocarcinoma.

Feng Y, Bai Z, Song J, Zhang Z Mol Med Rep. 2020; 23(2).

PMID: 33300075 PMC: 7723167. DOI: 10.3892/mmr.2020.11730.


Sodium homeostasis in the tumour microenvironment.

Leslie T, James A, Zaccagna F, Grist J, Deen S, Kennerley A Biochim Biophys Acta Rev Cancer. 2019; 1872(2):188304.

PMID: 31348974 PMC: 7115894. DOI: 10.1016/j.bbcan.2019.07.001.